title: Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil.
abstract: BACKGROUND
  Although ondansetron was found to be effective as an antiemetic in numerous clinical trials of highly emetogenic combination-chemotherapy regimens that included cisplatin, its role in milder emetogenic regimens has not been fully defined. To address its use with a widely used but less emetogenic regimen, we performed a double-blind, randomized clinical trial comparing ondansetron with dexamethasone and metoclopramide in patients with breast cancer receiving chemotherapy with cyclophosphamide, methotrexate, and fluorouracil.
  
  
  METHODS
  A total of 165 women with breast cancer from 14 Canadian centers who were about to receive this chemotherapy for the first time were randomly assigned to receive either ondansetron (n = 85) or dexamethasone plus metoclopramide (n = 80), a widely used, standard antiemetic regimen. The patients recorded the incidence of nausea, emesis, and other side effects in diaries, and these data were compared in the two groups.
  
  
  RESULTS
  The patients who received dexamethasone and metoclopramide had significantly less nausea during the first 24 hours after chemotherapy was begun. Otherwise, there were no statistically significant differences in efficacy between the regimens. The incidence of drowsiness and increased appetite was higher in the group given dexamethasone and metoclopramide.
  
  
  CONCLUSIONS
  For women with breast cancer who are being treated with cyclophosphamide, methotrexate, and fluorouracil, the efficacy of dexamethasone and metoclopramide in controlling nausea and vomiting equaled or exceeded that of ondansetron.
authors.affiliation: Department of Internal Medicine, University of Manitoba, Winnipeg, Canada.
authors.forename: M
authors.initials: M
authors.lastname: Levitt
authors.forename: D
authors.initials: D
authors.lastname: Warr
authors.forename: L
authors.initials: L
authors.lastname: Yelle
authors.forename: H L
authors.initials: HL
authors.lastname: Rayner
authors.forename: W S
authors.initials: WS
authors.lastname: Lofters
authors.forename: D J
authors.initials: DJ
authors.lastname: Perrault
authors.forename: K S
authors.initials: KS
authors.lastname: Wilson
authors.forename: J
authors.initials: J
authors.lastname: Latreille
authors.forename: M
authors.initials: M
authors.lastname: Potvin
authors.forename: E
authors.initials: E
authors.lastname: Warner
mesh_terms: D000704:Analysis of Variance; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D003907:Dexamethasone / Q000008:administration & dosage* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects; D008787:Metoclopramide / Q000008:administration & dosage* / Q000627:therapeutic use; D008875:Middle Aged; D009325:Nausea / Q000517:prevention & control; D017294:Ondansetron / Q000008:administration & dosage / Q000627:therapeutic use*; D012044:Regression Analysis; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control*
chemical_list: D017294:Ondansetron; D003907:Dexamethasone; D003520:Cyclophosphamide; D008787:Metoclopramide; D005472:Fluorouracil; D008727:Methotrexate